Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Aldactone, CaroSpir (1)

Analgesic (2) · Classic Psychedelic (1) · Lysergamide (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Aldosterone_antagonists|Mineralocorticoid (aldosterone) receptor antagonist]] (1) · [[:Category:Antiandrogens|Antiandrogen]] (1) · [[:Category:Potassium-sparing_diuretics|Potassium-sparing diuretic]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of LSD; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000034F-QINU`"', '"`UNIQ--vote-00000350-QINU`"', '"`UNIQ--vote-00000351-QINU`"', '"`UNIQ--vote-00000352-QINU`"', '"`UNIQ--vote-00000353-QINU`"' (1)

None (2) · 25 mg PO once daily for HFrEF and primary aldosteronism; up to 100 mg/d for ascites; 50-200 mg/d for hirsutism (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 25 mg, 50 mg, 100 mg tablets; 25 mg/5 mL oral suspension (CaroSpir) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 400 mg/d (acute primary aldosteronism diagnosis); 100-200 mg/d typical chronic (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Natriuresis at 2-3 days; endocrine effects (gynecomastia, antiandrogen action) over weeks (1)

None (2) · 4–6 hours (1) · Variable; biologically active metabolite carries effect beyond plasma half-life (1)

None (2) · 1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"' (1) · 2.5–3 hours (1)

None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~70% (oral; bioavailability and absorption are improved with food)'"`UNIQ--ref-00000355-QINU`"' (1)

None (2) · Avoid in pregnancy; antiandrogen effects can feminize a male fetus.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)